Goldfinch Bio Initiates Phase 1 Clinical Trial of GFB-887 for Kidney Disease

65

CAMBRIDGE, Mass.–(BUSINESS WIRE)–#conference–Initiated dosing in a Phase 1 clinical trial of GFB-887 for the treatment for kidney diseases associated with proteinuria & progressive renal disease…

 

 

http://www.businesswire.com/news/home/20190606005151/en/Goldfinch-Bio-Initiates-Phase-1-Clinical-Trial